Synakis is developing novel biomaterial-based treatments for ocular conditions. Created in https://BioRender.com.
Synakis is a pre-clinical biotech startup developing breakthrough biomaterial-based treatments for ocular diseases, including retinal detachment, glaucoma, and retinal degenerative diseases. Our mission is to restore vision and enhance the quality of life for patients.
Synakis’ core technology, SNK-125, is a proprietary hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous replacement for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Synakis Announces Close of Oversubscribed Pre-Seed Round
May 21, 2026
Synakis announced today the close of an oversubscribed CAD $2.6 million pre-seed financing round to advance SNK-125, its vitreous replacement therapy for retinal detachment. The round was co-led by Toronto Innovation Acceleration Partners (TIAP) and Chiefswood Private Capital Inc., with additional investment from the Ontario Centre of Innovation (OCI) and the Canadian Glycomics Network (GlycoNet).
Synakis Announced as 1 of 10 Companies to Receive Investment Through OCI’s Life Sciences Innovation Fund
May 11, 2026
Synakis welcomed Claudia Krywiak, President & CEO of Ontario Centre of Innovation (OCI), Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade, and MPP Michelle Cooper for the announcement that OCI has invested in Synakis through the Life Sciences Innovation Fund.
Upcoming Events
Want to meet our team and learn more about Synakis? Meet us at these upcoming events: